GE Healthcare Ltd. v. Johns Hopkins University
Pending - Instituted- Docket:
- IPR2026-00069
- Filed:
- 2025-10-21
An Inter Partes Review (IPR) proceeding initiated by GE Healthcare Ltd. challenging claims 1-3 of the patent as obvious over prior art.
Defendant
1 case as defendant.
The Johns Hopkins University is a private research university founded in 1876 in Baltimore, Maryland. As America's first research university, it is a major non-profit institution organized into ten academic divisions with multiple campuses and international centers. The university enrolls over 30,000 students and employs more than 27,000 total staff. Johns Hopkins has the highest federal research funding of any American university.
Johns Hopkins is a world-renowned operating entity focused on education, scientific research, and healthcare. Its major divisions include schools of Arts and Sciences, Engineering, Medicine, Nursing, and Public Health, as well as the Applied Physics Laboratory (APL), a major government defense contractor. The university is a leader in technology transfer, managing the commercialization of its research discoveries through Johns Hopkins Tech Ventures (JHTV). JHTV licenses university technologies to industry partners and helps form startup companies.
The university's patent-litigation posture, based on the provided data, is that of an operating company defending its intellectual property. The single tracked case shows Johns Hopkins as a defendant in a Patent Trial and Appeal Board (PTAB) proceeding, not as a plaintiff asserting its patents. This is consistent with the activities of a major research institution that licenses its extensive patent portfolio and may face challenges to its patents' validity from licensees or competitors.
The notable tracked case is GE Healthcare Ltd. v. Johns Hopkins University, an inter partes review proceeding before the PTAB initiated in 2025. The patent at issue in a related proceeding, No. 11,938,201, relates to radiopharmaceuticals for targeting a specific protein for imaging applications, highlighting the university's research focus in the medical and life sciences fields.
An Inter Partes Review (IPR) proceeding initiated by GE Healthcare Ltd. challenging claims 1-3 of the patent as obvious over prior art.